Inside STAT: GlaxoSmithKline CEO takes the company on a quest for identity

INSIDE A GLAXOSMITHKLINE PRODUCTION BUILDING IN MONTROSE, SCOTLAND, FOR ACTIVE PHARMACEUTICAL INGREDIENTS. (ANDY BUCHANAN/GETTY IMAGES)

It's been a little less than two years since Emma Walmsley took the helm of GlaxoSmithKline. For Walmsley, the biggest issue at hand is the drug giant's financial situation. When she took over the company, GSK's shares were at the level they were at in 1998, though they'd fluctuated dramatically in the years in between. But Walmsley is also trying to nail down the company's identity and sharpen its focus on pharmaceuticals. STAT's Matthew Herper and Ed Silverman have more on the company's history and Walmsley's efforts — read here.